Genmab A/S research snapshot
GMAB AI stock analysis reads Genmab A/S as a profitable antibody-medicine company whose economics are still led by royalties from partner-sold therapies, especially DARZALEX, while EPKINLY, Tivdak, Rina-S, and petosemtamab shape the next growth phase. At the August 2, 2026 data cutoff, GMAB closed at $28.87 on July 31 and StockAnalysis reported a $17.56 billion market capitalization. The opportunity rests on durable royalty growth and pipeline execution, while the Phase 3 EPCORE DLBCL-1 miss, debt from the Merus acquisition, drug-development outcomes, partner concentration, and valuation remain material risks. This is informational research, not investment advice.
Current price
$28.87 closing price on July 31, 2026
Market cap
About $17.56 billion
AI score
66 / 100
Rating
Profitable antibody-medicine business with strong technicals, balanced by clinical, partner, and leverage risk
Trend status
Short-term and long-term uptrends with a 10/10 technical rating; price below the 200-day average
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Genmab earns high-margin royalties on partner-sold antibody medicines and increasingly sells or co-commercializes EPKINLY and Tivdak while funding a larger proprietary oncology pipeline. | High |
| Moat | The moat combines antibody-engineering know-how, clinical evidence, patents, regulatory experience, global partners, and commercial relationships. It is narrower where revenue depends on partners and product exclusivity. | Medium |
| Management | Management must convert the Merus acquisition and internally developed assets into durable returns while preserving financial flexibility and maintaining disciplined pipeline spending. | Medium |
| Financial trend | FY2025 revenue was $3.720 billion, up 19%, and Q1 2026 revenue was $896 million, up 25%. Q1 reported net profit fell to $53 million as acquisition, integration, interest, and pipeline costs rose. | High |
| Valuation | StockAnalysis showed a trailing PE near 21.4x, P/FCF near 20.1x, and PS near 4.5x on August 2. The share-statistics page has an ADS unit inconsistency, so valuation multiples are more reliable than a raw book-value-per-share calculation from that display. | Medium |
| Technical trend | ChartMill rated GMAB 10/10 for both technical and setup quality with short-term and long-term uptrends. Price sits above the rising 20-day and 50-day averages but below the declining 200-day average near $29.06. | Medium |
| Risk level | Risk is high because royalties are concentrated, the EPCORE DLBCL-1 trial missed its U.S. primary endpoint, clinical programs can fail, partners control important sales, acquisition debt raises fixed obligations, and drug pricing, patents, litigation, or regulation can reset expectations. | High |
| AI confidence | Reported financial facts and repeatable calculations are well supported. Exact price outcomes cannot be predicted reliably because trial, regulatory, partner, and market events can change the path quickly. | High data confidence |
| Investment certainty | Medium-low certainty. The business has valuable assets and positive cash generation, but the margin of safety depends on underwriting concentration and post-acquisition execution rather than assuming the pipeline will succeed. | Medium-low |
GMAB AI stock forecast
The GMAB AI stock forecast uses a three-year scenario framework around the July 31, 2026 closing price of $28.87 and $1.31 trailing EPS. The model produced values near $51.5 in the bullish case, $33.4 in the base case, and $14.3 in the bearish case. These are model outputs, not price targets or promises.
$48 to $55
More likely if DARZALEX and Kesimpta royalties keep compounding, EPKINLY and Tivdak expand successfully, Rina-S and petosemtamab advance, the EPCORE DLBCL-2 readout is positive, Merus integration is orderly, and investors assign a premium earnings multiple to durable antibody-medicine growth.
$31 to $36
More likely if revenue compounds in the low to mid teens, DARZALEX sales keep growing as reported in Q2 2026, debt is serviced without constraining development, and the market values GMAB near a low-20s earnings multiple.
$13 to $16
More likely if royalty growth slows, the EPCORE DLBCL-1 miss raises doubts across the epcoritamab program, partner sales or pricing disappoint, clinical or regulatory outcomes weaken the pipeline, integration costs remain elevated, or the market applies a lower multiple to a more leveraged biotechnology business.
GMAB AI technical analysis
GMAB AI technical analysis is a dated August 2, 2026 snapshot. ChartMill rated the stock 10/10 for technical and setup quality with short-term and long-term uptrends, a support zone near $27.73 to $27.91, resistance near $29.00 to $29.05 and $29.65 to $29.78, 20-day and 50-day moving averages near $28.84 and $27.04, and daily RSI near 57.07. The close used for this page is $28.87 on July 31, so live prices and volume should be checked before using these levels.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $28.87 | StockAnalysis closing price for July 31, 2026, used in the market-cap and scenario calculations. |
| Near support | $27.73 to $27.91 | ChartMill support zone formed by multiple trend lines and important moving averages across time frames. |
| Secondary support | $25.84 | ChartMill support from a weekly time frame trend line. |
| Tertiary support | $25.08 to $25.10 | ChartMill support zone formed by multiple weekly trend lines. |
| Moving averages | 20-day $28.84; 50-day $27.04; 200-day $29.06 | Price was above the rising 20-day and 50-day averages but below the declining 200-day average. |
| Resistance | $29.00 to $29.05 and $29.65 to $29.78 | ChartMill identified two resistance zones from trend lines in daily and multiple time frames. |
| Momentum | Short-term positive, neutral RSI | Daily RSI was 57.07 and daily stochastics were 52.83 in the ChartMill snapshot, while MACD was slightly below zero but rising. |
| Volume | About 1.87 million average shares | ChartMill average-volume snapshot. A resistance break is stronger when price and volume confirm each other. |
| Volatility | ATR about 2.73% | ChartMill classified the daily volatility context as medium, but clinical and regulatory news can create gaps beyond normal ranges. |
| Invalidation | Break below $27.73 | A decisive close below the $27.73 to $27.91 support zone weakens the setup and warrants a fresh review of price action, the 200-day average, and fundamentals. |
GMAB AI trading strategy
The GMAB AI trading strategy is a general framework for a biotechnology stock with royalty, earnings, clinical, and regulatory catalysts. It is not personalized advice and should be used only with live quotes, position sizing, earnings dates, pipeline calendars, and independent research.
Watch whether GMAB clears the $29.00 to $29.05 resistance with volume confirmation while royalty growth, product sales, and pipeline news remain consistent with the thesis. ChartMill noted a positive Pocket Pivot signal and rising short-term and long-term trends.
Set a maximum loss before entry. A close below $27.73 weakens the setup and should prompt a reassessment instead of automatic averaging down.
If GMAB retreats toward the $27.73 to $27.91 zone without a negative product, partner, clinical, or financing event, compare the move with Q1 revenue, royalty trends, debt service, pipeline timelines, and the next earnings report.
Do not treat every pullback as value. A change in DARZALEX economics, partner demand, trial data, or debt assumptions can impair the earnings path.
Track DARZALEX and Kesimpta sales, royalty mix, EPKINLY and Tivdak launches, Rina-S and petosemtamab milestones, EPCORE DLBCL-2 data expected in 2026, operating expenses, cash, borrowings, interest expense, repurchases, patent disputes, and competitor data.
Lower conviction if royalty growth and proprietary-product progress no longer offset pipeline spending, acquisition costs, interest burden, or product concentration.
Investment research summary
Genmab turns antibody discovery, clinical development, patents, regulatory expertise, partner relationships, and a growing commercial organization into royalties, product sales, and potential future oncology franchises.
The moat comes from differentiated antibody platforms, evidence behind approved medicines, intellectual property, partner networks, specialist development knowledge, and the cost and time required to build a comparable pipeline. It is constrained by dependence on partner commercialization and exclusivity periods.
The thesis can fail if royalty products slow, competitors take share, the EPCORE DLBCL-1 miss spreads to the broader epcoritamab program, drug pricing or patents weaken economics, pipeline programs fail, litigation creates disruption, Merus integration misses expectations, or debt and interest costs limit future investment.
Management should be judged on capital allocation after the Merus acquisition, debt reduction, buyback discipline, launch execution, clinical prioritization, and whether R&D spending creates durable assets rather than a larger but lower-return organization.
Oncology and autoimmune antibody medicines remain a long-term innovation market, but returns depend on differentiated clinical benefit, safety, pricing, access, patents, manufacturing, and distribution. Large theoretical markets alone do not guarantee product value.
GMAB is profitable and trades on a moderate reported earnings and free-cash-flow multiple, but its margin of safety is shaped by royalty concentration, pipeline execution, and leverage after Merus. The raw share-count display needs ADS conversion context, so it should not be used alone for per-share balance-sheet ratios.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| GMAB price | $28.87 close on July 31, 2026 | StockAnalysis overview page, real-time price data sourced from CBOE | August 2, 2026 |
| Market capitalization and share-count check | $17.56 billion reported by StockAnalysis. $28.87 times about 613.8 million ADS-equivalent shares equals $17.72 billion, a 0.91% difference. The StockAnalysis 61.38 million share display is not directly comparable to its headline market cap and appears to need a 10x ADS conversion. | StockAnalysis statistics and financial_rigor.py market-cap verification | August 2, 2026 |
| FY2025 revenue | $3.720 billion, up 19.19% year over year | Genmab 2025 Annual Report via StockAnalysis financials | August 2, 2026 |
| FY2025 net profit | $963 million, down 15% from FY2024 | Genmab 2025 Annual Report via StockAnalysis financials | August 2, 2026 |
| Q1 2026 revenue and net profit | $896 million revenue, up 25.31% year over year, with $562 million DARZALEX royalties. Net profit was $53 million as acquisition, integration, interest, and pipeline costs rose. | StockAnalysis quarterly financials | August 2, 2026 |
| Q2 2026 DARZALEX net sales | Worldwide net trade sales of DARZALEX totaled USD 4,207 million in Q2 2026, with USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world | Genmab company announcement, July 15, 2026, DARZALEX Q2 2026 sales | August 2, 2026 |
| Q1 2026 liquidity and borrowings | $1,521 million cash and investments, plus $5,351 million total debt, a net debt position of about $3,830 million at March 31, 2026 | StockAnalysis quarterly balance sheet | August 2, 2026 |
| Analyst consensus and price target | 11 analysts rated GMAB Strong Buy with an average 12-month target of $37.96, a median of $40, a low of $32, and a high of $43 | StockAnalysis forecast, consensus from S&P Global Market Intelligence and TipRanks | August 2, 2026 |
| Technical levels | Technical and setup rating 10/10; support $27.73 to $27.91, $25.84, and $25.08 to $25.10; resistance $29.00 to $29.05 and $29.65 to $29.78; 20-day SMA $28.84; 50-day SMA $27.04; 200-day SMA $29.06; RSI 57.07 | ChartMill technical analysis | August 2, 2026 |
This GMAB AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 2, 2026 and can be wrong if financial results, clinical data, regulatory decisions, partner sales, patents, interest rates, debt, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
